Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CATX
Strong SellPerspective Therapeutics, Inc. · Healthcare · United States · $355M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Perspective Therapeutics, Inc. develops advanced radiopharmaceuticals and medical devices, specializing in targeted alpha-particle therapies for cancer treatment. The company's competitive moat is driven by its proprietary isotope supply chain, particularly Lead-212, and its specialized brachytherapy product line. It operates as a highly specialized pioneer in the rapidly growing radiopharmaceutical oncology sector.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.8M | 0 | 0 | 0 | — | — | 0.3M | 0.4M | -49.2% |
| EPS | -0.06 | -0.43 | -1.23 | -1.40 | — | -1.33 | -0.99 | -1.02 | — |
| Shares | 114.0M | 114.0M | 70.7M | 74.3M | -34.8% | — | — | — | — |
| Debt | 0.5M | 2.6M | 4.1M | 3.3M | 83.8% | 4.0M | — | — | — |
| Equity | 61.3M | 75.2M | 290.7M | 207.0M | 50.1% | — | — | — | — |
| Op CF | -7.7M | -36.9M | -18.3M | -82.5M | — | -93.1M | — | — | — |
| Inv CF | -0.3M | 24.4M | -218.9M | 41.2M | — | — | — | — | — |
| Fin CF | 56.0K | 0.8M | 289.4M | 10.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CATX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CATX | Perspective Therapeutics, Inc.(you) | $355M | 14 | Strong Sell |
| MOBI | Mobia Medical, Inc. | $378M | 16 | Strong Sell |
| CV | CapsoVision, Inc. | $297M | 12 | Strong Sell |
| CLPT | ClearPoint Neuro, Inc. | $474M | 14 | Strong Sell |
| PACB | Pacific Biosciences of California, Inc. | $435M | 17 | Strong Sell |
| TLSI | TriSalus Life Sciences, Inc. | $297M | 20 | Strong Sell |
| LAB | Standard BioTools Inc. | $252M | 18 | Strong Sell |
| PAIN.V | Vector Science and Therapeutics Corp. | $244M | 9 | Strong Sell |
| RXST | RxSight, Inc. | $293M | 23 | Sell |
| IMR.AX | Imricor Medical Systems, Inc. | $506M | 8 | Strong Sell |
Peer medians: ROE -24.4% · P/E 31.0x · Gross margin 58.8%